NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced that the company will host a virtual Investor Event on Monday, October 12, 2020 at 8:00 a.m. EDT to discuss results from the Phase 3 True North trial evaluating Zeposia® (ozanimod) in patients with moderate to severe ulcerative colitis, which will be presented at United European Gastroenterology (UEG) Week 2020.
Company executives will provide an overview of results and address questions from investors and analysts.
Investors and the general public are invited to listen to a live webcast at http://investor.bms.com or by calling the U.S. toll free at 1-800-458-4121 or international +1 313-209-6672, confirmation code: 9071827, or using this link, which becomes active 15 minutes prior to the scheduled start time and entering your information to be connected. Materials related to the webcast will be available at the same website prior to the event. An archived edition of the session will be available later that day.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.